



Hope Funds for Cancer Research

**Press Release
For Immediate Release**

Media Contact: John Wells
media@hope-funds.org
212-769-2170

[here](#)

Board Chair Lewis C. Cantley Discusses the Importance of Hope Funds and His Approach to Cancer Research in Video

For Immediate Release
Media Contact:
John A. Wells
212-769-2170
media@hope-funds.org

NEWPORT, RI -- November 29, 2018 -- Dr. Lewis C. Cantley, Director of the Sandra and Edward Meyer Cancer Center at Weill Cornell Medical College and New York Presbyterian Hospital, discusses the important work of Hope Funds for Cancer Research in a video released by the organization.

Dr. Cantley, Chair of the Hope Funds Board of Trustees since 2017, is known for his groundbreaking discovery of an enzyme that has led to the development of targeted cancer treatment drugs.

The approximately two-minute video, produced by television journalist Gary Jobson, a Hope Funds Trustee, may be viewed [here](#).

"We are pleased to share this conversation with Dr. Cantley, who is doing an outstanding job as Chair of the Hope Funds Board," said Leah Rush Cann, Chair of the Executive Committee. "He knows well the positive, enduring impact of Hope Funds on its fellows and their important work."

Lewis C. Cantley, Ph.D.

Lewis C. Cantley, Ph.D., is Director of the Sandra and Edward Meyer Cancer Center at Weill Cornell Medical College and New York Presbyterian Hospital. Dr. Cantley graduated from West Virginia Wesleyan College in 1971. He obtained a Ph.D. in biophysical chemistry from Cornell University in 1975 and did postdoctoral training at Harvard University. Prior to taking the position at Weill Cornell, he taught and did research in biochemistry, physiology and cancer biology in Boston, most recently at Beth Israel Deaconess Medical Center and Harvard Medical. His laboratory discovered the PI 3-Kinase pathway that plays a critical role in insulin signaling and in cancers. Dr. Cantley is a member of the National Academy of Sciences and has received a number of awards for his research, including



the 2005 Pezcoller Foundation-AACR International Award for Cancer Research, the 2009 Rolf Luft Award for Diabetes and Endocrinology Research, the 2013 Breakthrough in Life Sciences Prize and the 2015 Canada Gairdner International Award.



Hope Funds for Cancer Research

Hope Funds for Cancer Research was formed in 2006 to establish a funding vehicle that would take a rational scientific, medical, and investment approach to making grants for the most innovative and promising research efforts to address the most difficult-to-treat cancers, including pancreatic, lung, liver, sarcomas, esophageal, brain, gastric, renal and ovarian cancers, as well as rare leukemias, lymphomas and MDS. These cancers are insidiously aggressive illnesses that kill most of their victims within months, even with aggressive chemotherapy. The Trustees of the Hope Funds for Cancer Research believe that funding young, innovative researchers will lead to breakthroughs in these areas and increase life expectancy for those with these types of cancers. The Hope Funds for Cancer Research is a 509 (a)(1) charity under 501(c)(3) of the Internal Revenue Service's code.

For additional information about the organization, please visit www.hope-funds.org or call 401-847-3286.

Hope Funds for Cancer Research: Advancing innovative research in understudied cancers



Hope Funds for Cancer Research is an independent and unaffiliated non-profit organization

11/29/2018- 6
- End -

Hope Funds for Cancer Research, 174 Bellevue Avenue, Suite 208, Newport, RI 02840

[SafeUnsubscribe™ {recipient's email}](#)

[Forward email](#) | [Update Profile](#) | [About our service provider](#)

Sent by media@hope-funds.org in collaboration with



Try it free today